http://purl.org/np/RAUAYZmAKq3rEJ358us_fDRB-iscbNoPTLJEkCustX67c#Head http://purl.org/np/RAUAYZmAKq3rEJ358us_fDRB-iscbNoPTLJEkCustX67c http://www.nanopub.org/nschema#hasAssertion http://purl.org/np/RAUAYZmAKq3rEJ358us_fDRB-iscbNoPTLJEkCustX67c#assertion http://purl.org/np/RAUAYZmAKq3rEJ358us_fDRB-iscbNoPTLJEkCustX67c http://www.nanopub.org/nschema#hasProvenance http://purl.org/np/RAUAYZmAKq3rEJ358us_fDRB-iscbNoPTLJEkCustX67c#provenance http://purl.org/np/RAUAYZmAKq3rEJ358us_fDRB-iscbNoPTLJEkCustX67c http://www.nanopub.org/nschema#hasPublicationInfo http://purl.org/np/RAUAYZmAKq3rEJ358us_fDRB-iscbNoPTLJEkCustX67c#pubinfo http://purl.org/np/RAUAYZmAKq3rEJ358us_fDRB-iscbNoPTLJEkCustX67c http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.nanopub.org/nschema#Nanopublication http://purl.org/np/RAUAYZmAKq3rEJ358us_fDRB-iscbNoPTLJEkCustX67c#assertion http://purl.obolibrary.org/obo/DOID_0060224 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Disease http://purl.org/np/RAUAYZmAKq3rEJ358us_fDRB-iscbNoPTLJEkCustX67c#association http://www.w3.org/1999/02/22-rdf-syntax-ns#object http://purl.obolibrary.org/obo/DOID_0060224 http://purl.org/np/RAUAYZmAKq3rEJ358us_fDRB-iscbNoPTLJEkCustX67c#association http://www.w3.org/1999/02/22-rdf-syntax-ns#predicate https://w3id.org/biolink/vocab/treats http://purl.org/np/RAUAYZmAKq3rEJ358us_fDRB-iscbNoPTLJEkCustX67c#association http://www.w3.org/1999/02/22-rdf-syntax-ns#subject https://identifiers.org/drugbank:DB00390 http://purl.org/np/RAUAYZmAKq3rEJ358us_fDRB-iscbNoPTLJEkCustX67c#association http://www.w3.org/1999/02/22-rdf-syntax-ns#type http://www.w3.org/1999/02/22-rdf-syntax-ns#Statement http://purl.org/np/RAUAYZmAKq3rEJ358us_fDRB-iscbNoPTLJEkCustX67c#association http://www.w3.org/2000/01/rdf-schema#label in adults digoxin is indicated for the treatment of mild to moderate heart failure and for the control of resting ventricular rate in patients with chronic atrial fibrillation 1 in pediatric patients with heart failure digoxin increases myocardial contractility digoxin oral solution usp is indicated for the treatment of mild to moderate heart failure digoxin increases left ventricular ejection fraction and improves heart failure symptoms as evidenced by increased exercise capacity and decreased heart failure related hospitalizations and emergency care while having no effect on mortality where possible digoxin should be used with a diuretic and an angiotensin converting enzyme inhibitor but an optimal order for starting these three drugs cannot be specified digoxin increases myocardial contractility in pediatric patients with heart failure digoxin oral solution usp is indicated for the control of resting ventricular response rate in patients with chronic atrial fibrillation digoxin should not be used for the treatment of multifocal atrial tachycardia http://purl.org/np/RAUAYZmAKq3rEJ358us_fDRB-iscbNoPTLJEkCustX67c#association https://w3id.org/biolink/vocab/association_type https://w3id.org/biolink/vocab/ChemicalToDiseaseOrPhenotypicFeatureAssociation http://purl.org/np/RAUAYZmAKq3rEJ358us_fDRB-iscbNoPTLJEkCustX67c#association https://w3id.org/biolink/vocab/provided_by https://w3id.org/um/NeuroDKG http://purl.org/np/RAUAYZmAKq3rEJ358us_fDRB-iscbNoPTLJEkCustX67c#association https://w3id.org/biolink/vocab/relation https://schema.org/TreatmentIndication https://identifiers.org/drugbank:DB00390 https://w3id.org/biolink/vocab/category https://w3id.org/biolink/vocab/Drug http://purl.org/np/RAUAYZmAKq3rEJ358us_fDRB-iscbNoPTLJEkCustX67c#provenance http://purl.org/np/RAUAYZmAKq3rEJ358us_fDRB-iscbNoPTLJEkCustX67c#assertion http://www.w3.org/ns/prov#wasAttributedTo https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAUAYZmAKq3rEJ358us_fDRB-iscbNoPTLJEkCustX67c#pubinfo http://purl.org/np/RAUAYZmAKq3rEJ358us_fDRB-iscbNoPTLJEkCustX67c#sig http://purl.org/nanopub/x/hasAlgorithm RSA http://purl.org/np/RAUAYZmAKq3rEJ358us_fDRB-iscbNoPTLJEkCustX67c#sig http://purl.org/nanopub/x/hasPublicKey MIGfMA0GCSqGSIb3DQEBAQUAA4GNADCBiQKBgQCODwZkXojpEKwk7Ldj2oPPfCstvqrcpgCaTLo235K7ht9C7E1GCkLvUuL2b4VWXJTcZx/hxgDauR8hUeYq/lS6tfTL9yFZsnfl+PWYDyz7vv6N+wJVx2LL8bO6ntCjcOzvW2t2WUeF12Sb6b3I6uOYP0N8iQKts1WasY/yEYKAHQIDAQAB http://purl.org/np/RAUAYZmAKq3rEJ358us_fDRB-iscbNoPTLJEkCustX67c#sig http://purl.org/nanopub/x/hasSignature BU+mmas358es4XTFz5yPMRyGZqtXe/rOgTqy1x1cCZOiv0OL/WH/8E1xTbT8aJcQA84iScbCF/aoQ2n1BIX8uJzTwG78LAL/AfLSpM6S7wRsj5OOHHBePd0uPIiI3s2g3du6FmZEyerR7SeLOjYmuy1z325MoHB3DvQABBF1CRw= http://purl.org/np/RAUAYZmAKq3rEJ358us_fDRB-iscbNoPTLJEkCustX67c#sig http://purl.org/nanopub/x/hasSignatureTarget http://purl.org/np/RAUAYZmAKq3rEJ358us_fDRB-iscbNoPTLJEkCustX67c http://purl.org/np/RAUAYZmAKq3rEJ358us_fDRB-iscbNoPTLJEkCustX67c http://purl.org/dc/terms/created 2021-06-12T16:39:49.728+02:00 http://purl.org/np/RAUAYZmAKq3rEJ358us_fDRB-iscbNoPTLJEkCustX67c http://purl.org/dc/terms/creator https://orcid.org/0000-0002-1468-3557 http://purl.org/np/RAUAYZmAKq3rEJ358us_fDRB-iscbNoPTLJEkCustX67c https://w3id.org/np/o/ntemplate/wasCreatedFromProvenanceTemplate http://purl.org/np/RANwQa4ICWS5SOjw7gp99nBpXBasapwtZF1fIM3H2gYTM http://purl.org/np/RAUAYZmAKq3rEJ358us_fDRB-iscbNoPTLJEkCustX67c https://w3id.org/np/o/ntemplate/wasCreatedFromPubinfoTemplate http://purl.org/np/RAA2MfqdBCzmz9yVWjKLXNbyfBNcwsMmOqcNUxkk1maIM http://purl.org/np/RAUAYZmAKq3rEJ358us_fDRB-iscbNoPTLJEkCustX67c https://w3id.org/np/o/ntemplate/wasCreatedFromTemplate http://purl.org/np/RAManV5GZI01JKzW_IPcfOXoiFTcZMmsV7qTCLkdzr4Gs